Key result
Irbesartan and atenolol similarly improved diastolic function, increasing the E/A ratio by 12% and 14% respectively, in patients with hypertensive left ventricular hypertrophy.
Why the study?
Does irbesartan improve diastolic function compared to atenolol in hypertensive patients with left ventricular hypertrophy?
RCT (n=115)
Double-blind
Does irbesartan improve diastolic function compared to atenolol in hypertensive patients with left ventricular hypertrophy?
Absolute Event Rate: 12% vs 14%
p-value: p=0.022 and <0.001
Both irbesartan and atenolol improve diastolic function to a similar degree in patients with hypertensive LV hypertrophy, although irbesartan provides a greater reduction in LV mass index.
No takes yet. Share an insight, caveat, or question.
Supports either irbesartan or atenolol for diastolic improvement in hypertensive LVH; confirms similar E/A effects while extending data on greater LV mass reduction with irbesartan.
Müller-Brunotte et al. (2005) conducted an RCT in Hypertensive left ventricular hypertrophy (n=115). Irbesartan vs. Atenolol was evaluated on Diastolic function (E/A ratio improvement) (p=0.022 and <0.001). Irbesartan and atenolol similarly improved diastolic function, increasing the E/A ratio by 12% and 14% respectively, in patients with hypertensive left ventricular hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: